Beyond Borders: global biotech report 2013
We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more in our 2013 industry report
Life Sciences deal sentiment scorecard
What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.
mHealth: Mobile tech poised to enable new era in health care
Discover the impact of technology innovation on health care and its stakeholders--patients, physicians, providers and payers.
Cash on the prescription 2012
In 2011, Big Pharma reported weaker working capital performance compared with 2010. Pressured to improve shareholder value, what measures can companies undertake to restore performance?
Beyond borders: global biotech report 2012
As serious resource constraints continue to plague the industry, how can biotech innovation be sustained? Delve into our 26th edition for key findings and insights.
Pharma's $100 billion growth gap
As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.
Progressions 2012: health care everywhere
Unsustainable costs and game-changing technologies are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report.
What Europe has to offer biotechnology companies
Europe has the potential to be a world leader in biotechnology, but more needs to be done by industry and regulatory authorities to get there.
Medical technology report 2011
Facing a confluence of risks — increasing regulatory, pricing and financing pressures, uncertain public policy climate and rapidly changing customer base — can medtech sustain innovation?

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm in today’s environment of rapid change in health care.

The life sciences community must explore a new course to address the changing climate — one driven by patients and focused on health outcomes.

From new market entrants and regulatory reform to expiring patents and rising prevalence of chronic disease, there are a myriad of hurdles to overcome.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

Biotechnology

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — around the world.

But with uncertain capital markets, increasing regulation, growing pricing pressures, and fierce competition in M&A, this sector faces numerous challenges.

We have been a pioneering presence in the biotechnology industry for many years. As the first professional services firm to build a practice dedicated to serving your industry, it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

We remain committed to your business, sharing our deep knowledge in leading reports and through our network of knowledgeable professionals.

Related content:

German biotechnology report 2011 (3.8 MB)
Swiss Biotech Report 2012 (3.5 MB)
Beyond Borders 2011: global biotechnology report
What Europe has to offer biotechnology companies
2011 Italian Biotechnology Report (3.4 MB)

Pharmaceutical

Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

Pharma 3.0 stands for the next big wave of improvements in health care – driven not just by new products, but by behavioral change. The future priority will be to identify interventions that are most promising, and then realign the behavior of all stakeholders — patients, providers and manufacturers — around these interventions.

We also publish a series of reports to bring you clear insights into assurance, tax, transaction, and other issues, as well as our annual report on pharmaceutical industry trends, Progressions.

Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

Related content:

Medical technology

Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

Related content:

Contact us

Contact a member of our Life Sciences team.

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.